Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
This study has been completed.
Sponsor:
University of Chicago
Collaborator:
Genentech
Information provided by (Responsible Party):
Rita Nanda, University of Chicago
ClinicalTrials.gov Identifier:
NCT00517361
First received: August 14, 2007
Last updated: October 24, 2012
Last verified: October 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | April 2012 |
| Primary Completion Date: | April 2011 (Final data collection date for primary outcome measure) |